If I remember correctly both dealt with debt incurred prior to the BioClonetics merger. I did not follow them as I did not feel at the time they would have a significant impact on the share price, and I still don't. The case I think will have an impact on Enzolytics, Inc. is the GLD vs SAGA case. Between the SEC filings, Kelli's court filings/deposition, Nasdaq removal, Enzolytics 11/20/23 PR, etc. I'm surprised the case is still continuing. To be fair I was also surprised (actually shocked) that SAGA was willing to put up five figures (I believe it was only $20,000 but would have to check) non refundable to appeal their Nasdaq delisting. A SPAC that claimed to have $19 in cash was willing to spend five figures on an appeal they should have knew they would lose is crazy. They had done nothing to correct the deficiencies that Nasdaq pointed out and should have known that they would lose their appeal. I believe they were just buying time with their delisting appeal challenge. Merganthaler may have a case, and therefore an impact on Enzolytics, Inc., but I only have access to courtlistener so I can't see all the information. From what I have seen of that case it is questionable as to who actually owns Enzolytics, Inc., but like I said I don't have access to all the information.
News 
Market Data 
Discover 
AI
